In order to develop high-quality pharmaceutical products, a traditional approach based the univariate or trial and error method was used in the past that led to several problems like non-reproducible, high-cost, and time consuming methods. To overcome these drawbacks, a new concept of the Design of Experiment (DoE) was introduced. DoE is a statistical element of the Quality by Design (QbD) approach introduced by British statistician Sir Ronald Fisher in 1925. The basic objectives of DoE are screening, optimization, and robustness. It involves the execution of experimental design on the basis of suitable variables along with statistical evaluation of obtained responses and exploration of the design space using mathematical or graphical approach. The statistical evaluation empowers to build up the quality of finished products and helps to meet the increasing demands for product of superior quality and standards. This article mainly focuses on the applications of DoE in pharmaceutical product development along with its objectives, design, and selection criteria.
Similar content being viewed by others
References
A. A. Hald, History of Mathematical Statistics from 1750 to 1930, Wiley Series in Probability and Statistics, Edinburgh – New York (1998).
R. A. Fisher, Statistical Methods for Research Workers, Oliver and Boyd, London (1925).
R. A. Fisher, J. Min. Agric. Gr. Brit.,33, 503 – 513 (1926).
R. A. Fisher, The Design of Experiments, Hafner Publishing Company, Inc., New York (1935).
S. N. Politis, P. Colombo, G. Coxlombo, et al., Drug Develop. Ind. Pharm.,43, 889 – 901 (2017).
Design of Experiments for Formulation Development. Pharmaceutical Technology (2005) [cited May 30, 2018]. Available from: http: // www.pharmtech.com/design-experiments-formulation-development-0?id=&sk=&date=&%0A%09%09%09& pageID=22 (Accessed June 20, 2018).
A. G. Mirani and V. B. Patravale, Design of experiments: Basic concepts and its application in pharmaceutical product development, in: Pharmaceutical Product Development, (Eds.:V. B. Patravale, J. I. Disouza, and M. T. Rustomjee), CRC Press – Taylor & Francis Group, New York (2016).
J. M. Juran, Juran on Quality by Design: the New Steps for Planning Quality into Goods and Services, Free Press, New York (1992).
U. S. Food and Drug Administration (2017). Final report from the FDA-EMA pilot program for the parallel assessment of quality-by-design elements of marketing applications. Available at: https: //wayback.archive-it.org/7993/ 20180125055008/https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm552716.htm (Accessed June 16, 2018).
B. Shah, D. Khunt, H. Bhatt, et al., Eur. J. Pharm. Sci.78, 54 – 66 (2015).
I. M. Savic, V. D. Marinkovic, L. Tasic, et al., Accred. Qual. Assur.,17, 627 – 33 (2012).
ICH Q8 (R2) Pharmaceutical Development, Guidelines (2009). Available at: https: // www.ich.org/fileadmin/Public_Web_Site/ICH Products/Guidelines/Quality/Q8 R1/Step4/Q8_R2_Guideline. pdf (Accessed July 8, 2018).
L. Zhang and S. Mao, Asian J. Pharm. Sci.,12, 1 – 8 (2017).
H. Guo and A. Mettas, Design of Experiments and Data Analysis, in Proceedings of Reliability and Maintainability Symposium (San Jose, CA, USA, 2010). Available at: https: //www.scribd.com/document/261112587/2010-RAMS-Doeand-Data-Analysis (Accessed July 11, 2018).
E. Marlowe, R. F. Shangraw, J. Pharm. Sci., 56, 498 – 504 (1967).
D. Granato and V. M. de Araújo Calado, The use and importance of design of experiments (DoE) in process modelling in food science and technology, in: Mathematical and Statistical Methods in Food Science and Technology (D. Granato, ed.), John Wiley & Sons, Inc., New York (2013), pp. 1 – 18.
S. Fontdecaba, P. Grima, and X. Tort-Martorell, The Am. Statistic,.68, 205 – 211 (2014).
R. R. Jivani, C. N. Patel, and N. P. Jivani, Indian J. Pharm. Sci.,74, 302 – 311 (2012).
N. A. Charoo, A. A. Shamsher, A. S. Zidan, et al., Int. J. Pharm.,423, 167 – 78 (2012).
M. Naeem, N. U. R. Rahman, J. A. Khan, et al., Lat. Am. J. Pharm.,32, 1196 – 1204 (2013).
N. Patel, S. Jain, P. Madan, et al., Drug Develop. Ind. Pharm.,42, 1894 – 1902 (2016).
M. A. Badawi and L. K. El-Khordagui, Eur. J. Pharm. Sci.,58, 44 – 54 (2014).
J. Kushner, B. A. Langdon, I. Hicks, et al., J. Pharm. Sci.,103, 527 – 538 (2013).
P. M. Kumar and A. Ghosh, Eur. J. Pharm. Sci.,96, 243 – 254 (2017).
E. Sánchez-López, M. A. Egea, A. Cano, et al., Colloid Surf. Biointerfaces, 145, 241 – 250 (2016).
L. Kumar, M. S. Reddy, R. S. Managuli, et al., Saudi Pharm. J.,23, 549 – 555 (2015).
N. S. K. Srinivas, R. Verma, G. P. Kulyadi, et al., Int. J. Nanomed.,12, 15 – 28 (2017).
G. N. Ferreira, M. G. R. Silva, A. G. M. Fraga, et al., Braz. J. Pharm. Sci.,50, 291 – 300 (2014).
P. Panzade, G. Shendarkar, S. Shaikh, et al., Adv. Pharm. Bull.,7, 399 – 408 (2017).
E. Maretti, C. Rustichelli, M. Romagnoli, et al., Int. J. Pharm.,511, 669 – 679 (2016).
M. H. Shariare, M. de Matas, P. York, et al., Int. J. Pharm.,408, 58 – 66 (2011).
M. Malladi and R. Jukanti. J. Drug Deliver. Sci. Technol.,35, 134 – 145 (2016).
M. S. Reddy, L Kumar, Z. Attari, et al., Indian J. Pharm. Sci.,79, 16 – 28 (2017).
P. F. Chavez, P. Lebrun, P. Y. Sacréet, et al., Int. J. Pharm.,486(1 – 2), 13 –20 (2015).
S. I. Badawy, A. S. Narang, K. R. LaMarche, et al., J. Pharm. Sci.,105(1), 168 – 81 (2016).
T. Tol, N. Kadam, N. Raotole, et al., J. Chromatogr., 1432, 26 – 38 (2016).
B. Gu and D. J. Burgess, Int. J. Pharm.,495(1), 393 – 403 (2015).
A. Al-Gheethi, E. Noman, R. M. S. Radin Mohamed, et al. J. Hazard. Mater., 365, 883 – 894 (2019).
M. Sakr, R. Hanafi, M. Fouad, et al. Spectrochim. Acta Mol. Biomol. Spectrosc., 208, 114 – 123 (2019).
A. Nair, D. Khunt, and M. Misra. Powder Technol., 342, 156 – 65 (2019).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dhoot, A.S., Fernandes, G.J., Naha, A. et al. Design of Experiments in Pharmaceutical Development. Pharm Chem J 53, 730–735 (2019). https://doi.org/10.1007/s11094-019-02070-4
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11094-019-02070-4